Shares of Merck KGaA (OTCMKTS:MKKGY – Get Free Report) have received a consensus recommendation of “Reduce” from the six analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have given a hold recommendation to the company.
A number of analysts have weighed in on the stock. HSBC raised shares of Merck KGaA to a “hold” rating in a report on Monday, July 6th. Zacks Research downgraded shares of Merck KGaA from a “hold” rating to a “strong sell” rating in a report on Monday, October 12th. Finally, UBS Group lowered shares of Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th.
View Our Latest Stock Analysis on MKKGY
Merck KGaA Stock Performance
Shares of MKKGY traded up $0.20 during mid-day trading on Friday, hitting $32.27. The company’s stock had a trading volume of 113,186 shares, compared to its average volume of 83,126. The stock’s 50-day moving average is $31.41 and its two-hundred day moving average is $30.35. The firm has a market capitalization of $20.85 billion, a PE ratio of 16.63, a price-to-earnings-growth ratio of 3.03 and a beta of 0.95. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.09 and a current ratio of 1.69. Merck KGaA has a one year low of $23.73 and a one year high of $34.19.
About Merck KGaA
Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. The company operates independently from Merck & Co, Inc, the U.S.-based company that uses the Merck name in the United States and Canada.
Merck KGaA operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, analytical technologies and bioprocessing solutions used by pharmaceutical and biotechnology companies, academic institutions and industrial laboratories.
Further Reading
- Five stocks we like better than Merck KGaA
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
